Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

CAN-2409, when administered with valacyclovir, is designed to induce ... by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor ...

every 8 hPrimary varicella: Acyclovir 10 mg/kg iv. every 8 h Valganciclovir 900 mg q.d. Ganciclovir 1 g p.o. t.i.d. Valacyclovir 2 g p.o. q.i.d. (for kidney recipients only)Pre-emptive therapy ...

Missions are undertaken as part of regular (usually annual) consultations under Article IV of the IMF's Articles of Agreement, in the context of a request to use IMF resources (borrow from the IMF), ...